Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional study.
Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Cancer Survivors
/ statistics & numerical data
Combined Modality Therapy
Cross-Sectional Studies
Cyclophosphamide
/ administration & dosage
Doxorubicin
/ administration & dosage
Fatigue
/ etiology
Female
Follow-Up Studies
Hematopoietic Stem Cell Transplantation
/ adverse effects
Humans
Lymphoma, Non-Hodgkin
/ therapy
Male
Middle Aged
Prednisone
/ administration & dosage
Prognosis
Quality of Life
Rituximab
/ administration & dosage
Time Factors
Transplantation, Autologous
Vincristine
/ administration & dosage
Young Adult
cross-sectional study
long-term fatigue
long-term survivors
non-Hodgkin lymphomas
risk factors
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
01 07 2019
01 07 2019
Historique:
received:
03
09
2018
revised:
06
02
2019
accepted:
06
02
2019
pubmed:
23
3
2019
medline:
25
3
2020
entrez:
23
3
2019
Statut:
ppublish
Résumé
Long-term survivors of non-Hodgkin lymphoma (NHL) must cope with treatment complications and late toxicities that affect their health-related quality of life. Little is known about the risk-to-benefit ratio of new agents like rituximab. The impact of treatment regimens and health disorders on long-term fatigue levels was investigated in a cross-sectional study. Two self-administered questionnaires, the 20-item Multidimensional Fatigue Inventory (MFI-20) and a Life Situation Questionnaire, were mailed in 2015 to NHL survivors enrolled onto 12 successive clinical studies (1993-2010) conducted by the Lymphoma Study Association. Private addresses were obtained for 3317 survivors, of whom 1671 (50%) returned the questionnaires. Severe fatigue was defined as MFI-20 scores ≥60 on dimension scales scored from 0 to 100. Linear regression models were used to assess factors that were linked to increased fatigue levels. The study population included 906 men and 765 women, and the median age was 64 years (age range, 24-95 years). Overall, 811 survivors had received cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP)-like chemotherapy, 518 had received high-dose CHOP, and 342 had undergone upfront autologous stem cell transplantation; 829 survivors also had received rituximab. In total, 1100 survivors (66%) reported 1 or more late health disorders. Severe fatigue was reported by 602 survivors (37%). Increased fatigue levels were associated (P < .001) with increased age, obesity, and the presence of health disorders, but not with initial treatment or rituximab. The survey confirms that high proportions long-term NHL survivors have severe fatigue. The results suggest that initial treatment and the receipt of rituximab have no influence on the development of long-term fatigue.
Sections du résumé
BACKGROUND
Long-term survivors of non-Hodgkin lymphoma (NHL) must cope with treatment complications and late toxicities that affect their health-related quality of life. Little is known about the risk-to-benefit ratio of new agents like rituximab. The impact of treatment regimens and health disorders on long-term fatigue levels was investigated in a cross-sectional study.
METHODS
Two self-administered questionnaires, the 20-item Multidimensional Fatigue Inventory (MFI-20) and a Life Situation Questionnaire, were mailed in 2015 to NHL survivors enrolled onto 12 successive clinical studies (1993-2010) conducted by the Lymphoma Study Association. Private addresses were obtained for 3317 survivors, of whom 1671 (50%) returned the questionnaires. Severe fatigue was defined as MFI-20 scores ≥60 on dimension scales scored from 0 to 100. Linear regression models were used to assess factors that were linked to increased fatigue levels.
RESULTS
The study population included 906 men and 765 women, and the median age was 64 years (age range, 24-95 years). Overall, 811 survivors had received cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP)-like chemotherapy, 518 had received high-dose CHOP, and 342 had undergone upfront autologous stem cell transplantation; 829 survivors also had received rituximab. In total, 1100 survivors (66%) reported 1 or more late health disorders. Severe fatigue was reported by 602 survivors (37%). Increased fatigue levels were associated (P < .001) with increased age, obesity, and the presence of health disorders, but not with initial treatment or rituximab.
CONCLUSIONS
The survey confirms that high proportions long-term NHL survivors have severe fatigue. The results suggest that initial treatment and the receipt of rituximab have no influence on the development of long-term fatigue.
Substances chimiques
Rituximab
4F4X42SYQ6
Vincristine
5J49Q6B70F
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Prednisone
VB0R961HZT
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2291-2299Informations de copyright
© 2019 American Cancer Society.
Références
Younes A, Ansell S, Fowler N, et al. The landscape of new drugs in lymphoma. Nat Rev Clin Oncol. 2017;14:335-346.
Fitoussi O, Belhadj K, Mounier N, et al. Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. Haematologica. 2011;96:1136-1143.
Chiappella A, Martelli M, Angelucci E, et al. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Lancet Oncol. 2017;18:1076-1088.
Bower JE, Bak K, Berger A, et al. Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical Oncology clinical practice guideline adaptation. J Clin Oncol. 2014;32:1840-1850.
Surbone A, Tralongo P. Categorization of cancer survivors: why we need it. J Clin Oncol. 2016;34:3372-3374.
Organisation for Economic Co-operation and Development (OECD). Classifying Education Programmes: Manual for ISCED-97 Implementation in OECD Countries, 1999 Edition. Paris, France: OECD; 1999.
Flechtner H, Ruffer JU, Henry-Amar M, et al. Quality of life assessment in Hodgkin's disease: a new comprehensive approach. First experiences from the EORTC/GELA and GHSG trials. EORTC Lymphoma Cooperative Group. Groupe d'Etude des Lymphomes de l'Adulte and German Hodgkin Study Group. Ann Oncol. 1998;9(suppl 5):S147-S154.
van der Kaaij MAE, Heutte N, Meijnders P, et al. Parenthood in survivors of Hodgkin lymphoma: an EORTC-GELA general population case-control study. J Clin Oncol. 2012;30:3854-3863.
Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995;39:315-325.
Kuhnt S, Ernst J, Singer S, et al. Fatigue in cancer survivors-prevalence and correlates. Onkologie. 2009;32:312-317.
Zelenetz AD, Gordon LI, Wierda WG, et al; National Comprehensive Cancer Network. Non-Hodgkin's lymphomas, version 4.2014. J Natl Compr Canc Netw. 2014;12:1282-1303.
Schwarz R, Krauss O, Hinz A. Fatigue in the general population. Onkologie. 2003;26:140-144.
Efron B, Tibshirani RJ. An Introduction to the Bootstrap. 1st ed. New York: CRC Press; 1994.
Anthony S, Hebel P, Garrel A, et al. Conduct of epidemiologic studies in French cancer survivors: methods, difficulties encountered and solutions provided. Lessons learned from the SIMONAL study on long-term toxicities after non-Hodgkin lymphoma treatment. Bull Cancer (Paris). 2017;104:221-231.
Bower JE. Cancer-related fatigue-mechanisms, risk factors, and treatments. Nat Rev Clin Oncol. 2014;11:597-609.
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Cancer-Related Fatigue. Version 2.2018. Fort Washington, PA: NCCN; 2018.
Loge JH, Ekeberg O, Kaasa S. Fatigue in the general Norwegian population: normative data and associations. J Psychosom Res. 1998;45:53-65.
van de Poll-Franse LV, Mols F, Gundy CM, et al. Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population. Eur J Cancer. 2011;47:667-675.
Waldmann A, Schubert D, Katalinic A. Normative data of the EORTC QLQ-C30 for the German population: a population-based survey [serial online]. PLoS One. 2013;8:e74149.
Husson O, Prins JB, Kaal SEJ, et al. Adolescent and young adult (AYA) lymphoma survivors report lower health-related quality of life compared to a normative population: results from the PROFILES registry. Acta Oncol. 2017;56:288-294.
Seland M, Holte H, Bjoro T, et al. Chronic fatigue is prevalent and associated with hormonal dysfunction in long-term non-Hodgkin lymphoma survivors treated with radiotherapy to the head and neck region. Leuk Lymphoma. 2015;56:3306-3314.
Heutte N, Flechtner HH, Mounier N, et al. Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. Lancet Oncol. 2009;10:1160-1170.
Kreissl S, Mueller H, Goergen H, et al. Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group. Lancet Oncol. 2016;17:1453-1462.
Ye F, Moon DH, Carpenter WR, et al. Comparison of patient report and medical records of comorbidities: results from a population-based cohort of patients with prostate cancer. JAMA Oncol. 2017;3:1035-1042.